إعلان
إعلان

STRO

STRO logo

Sutro Biopharma, Inc.

11.47
USD
برعاية
+0.61
+5.57%
٠٦ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

11.41

-0.06
-0.52%

تقارير أرباح STRO

النسبة الإيجابية المفاجئة

STRO تفوق 14 من 29 آخر التقديرات.

48%

التقرير التالي

بيانات التقرير القادم
١١ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$8.51M
/
-$4.40
التغير الضمني من Q3 25 (Revenue/ EPS)
-12.23%
/
-34.33%
التغير الضمني من Q4 24 (Revenue/ EPS)
-42.55%
/
-50.56%

Sutro Biopharma, Inc. earnings per share and revenue

On ٠٦ نوفمبر ٢٠٢٥, STRO reported earnings of -6.70 USD per share (EPS) for Q3 25, missing the estimate of -4.22 USD, resulting in a -58.49% surprise. Revenue reached 9.69 مليون, compared to an expected 9.31 مليون, with a 4.07% difference. The market reacted with a -13.36% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 المحللين forecast an EPS of -4.40 USD, with revenue projected to reach 8.51 مليون USD, implying an نقصان of -34.33% EPS, and نقصان of -12.23% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
For Q3 2025, Sutro Biopharma, Inc. reported EPS of -$6.70, missing estimates by -58.49%, and revenue of $9.69M, 4.07% above expectations.
The stock price moved down -13.36%, changed from $9.42 before the earnings release to $8.16 the day after.
The next earning report is scheduled for ١١ مارس ٢٠٢٦.
Based on 12 المحللين, Sutro Biopharma, Inc. is expected to report EPS of -$4.40 and revenue of $8.51M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان